search
Back to results

Effect of Creatine Monohydrate on Functional Muscle Strength in Children With FSHD

Primary Purpose

Facio-Scapulo-Humeral Dystrophy, FSHD2, FSHD1

Status
Completed
Phase
Not Applicable
Locations
Australia
Study Type
Interventional
Intervention
Creatine Monohydrate
Placebo
Sponsored by
Murdoch Childrens Research Institute
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Facio-Scapulo-Humeral Dystrophy focused on measuring fshd, creatine monohydrate, children, pediatrics, Facio-Scapulo-Humeral Dystrophy

Eligibility Criteria

5 Years - 18 Years (Child, Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Is between the ages of 5 and 18 years inclusive at the time of randomisation;
  • Has a confirmed genetic diagnosis of Facioscapulohumeral Muscular Dystrophy (FSHD) types 1 or 2;
  • Has a legally acceptable representative capable of understanding the informed consent document and providing consent on the participant's behalf.

Exclusion Criteria:

  • Has clinically significant elevation in plasma creatinine level or unexplained hypertension at screening;
  • Has a prior diagnosis of chronic renal failure;
  • Has a known hypersensitivity to creatine monohydrate of maltodextrin placebo;
  • Patients already taking any medications to increase muscle bulk or strength or concomitant use of regular sodium valproate, corticosteroids of alpha agonists such as salbutamol.

Sites / Locations

  • The Royal Children's Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Active Comparator

Arm Label

Group A - Active/Placebo

Group B - Placebo/Active

Arm Description

Participants will receive 3 months of creatine monohydrate followed by a 6 week washout period followed by 3 months of placebo.

Participants will receive 3 months of placebo followed by a 6 week washout period followed by 3 months of creatine monohydrate.

Outcomes

Primary Outcome Measures

Motor Function Measure for Neuromuscular disease
Composite functional outcome measure

Secondary Outcome Measures

Muscle Magnetic Resonance Imaging
Muscle Ultrasound Scan
Performance of the Upper Limb Measure
ACTIVILIM
PedsQL Neuromuscular
FSH-COM
FSHD specific composite measure
FSH-Health Index (Pediatric Version)
Patient reported outcome measure specific for patients with FSHD.
Six Minute Walk Test
FSHD Severity Score
Quantitative muscle strength testing
GPX3 Level
Possible biomarker of disease severity in FSHD
Step Counter
Physical activity measure
Laboratory safety monitoring
bloods and urine safety testing (urea and electrolytes, urine plasma creatine:creatinine ratios)

Full Information

First Posted
October 26, 2016
Last Updated
February 4, 2023
Sponsor
Murdoch Childrens Research Institute
search

1. Study Identification

Unique Protocol Identification Number
NCT02948244
Brief Title
Effect of Creatine Monohydrate on Functional Muscle Strength in Children With FSHD
Official Title
Effect of Creatine Monohydrate on Functional Muscle Strength and Muscle Mass in Children With FSHD: a Multi-centre, Randomised, Double-blind Placebo-controlled Crossover Trial
Study Type
Interventional

2. Study Status

Record Verification Date
February 2023
Overall Recruitment Status
Completed
Study Start Date
October 31, 2017 (Actual)
Primary Completion Date
January 31, 2021 (Actual)
Study Completion Date
July 1, 2022 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Murdoch Childrens Research Institute

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This multi-centre, randomised, double-blind, placebo-controlled crossover trial will compare changes in strength-related motor function following treatment with creatine monohydrate to treatment with placebo, as measured by the Motor Function Measure, from baseline to 12 weeks. Eligible subjects will undergo baseline assessments then will be randomised to either creatine monohydrate therapy or placebo for three months, followed by a six week wash-out period, then crossover to a further three months of therapy with either placebo or creatine. Subjects will undergo clinical assessments and study safety assessments at the beginning and end of each treatment period. The study will begin recruitment in early 2017.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Facio-Scapulo-Humeral Dystrophy, FSHD2, FSHD1
Keywords
fshd, creatine monohydrate, children, pediatrics, Facio-Scapulo-Humeral Dystrophy

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
11 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Group A - Active/Placebo
Arm Type
Active Comparator
Arm Description
Participants will receive 3 months of creatine monohydrate followed by a 6 week washout period followed by 3 months of placebo.
Arm Title
Group B - Placebo/Active
Arm Type
Active Comparator
Arm Description
Participants will receive 3 months of placebo followed by a 6 week washout period followed by 3 months of creatine monohydrate.
Intervention Type
Dietary Supplement
Intervention Name(s)
Creatine Monohydrate
Intervention Description
Synthetically produced dietary supplement Creatine Monohydrate will be used in powder form reconstituted to a drink. The dosage will be 100mg/kg/day up to a maximum of 10 grams daily.
Intervention Type
Dietary Supplement
Intervention Name(s)
Placebo
Intervention Description
Placebo
Primary Outcome Measure Information:
Title
Motor Function Measure for Neuromuscular disease
Description
Composite functional outcome measure
Time Frame
3 months
Secondary Outcome Measure Information:
Title
Muscle Magnetic Resonance Imaging
Time Frame
3 months
Title
Muscle Ultrasound Scan
Time Frame
3 months
Title
Performance of the Upper Limb Measure
Time Frame
3 months
Title
ACTIVILIM
Time Frame
3 Months
Title
PedsQL Neuromuscular
Time Frame
3 months
Title
FSH-COM
Description
FSHD specific composite measure
Time Frame
3 months
Title
FSH-Health Index (Pediatric Version)
Description
Patient reported outcome measure specific for patients with FSHD.
Time Frame
3 months
Title
Six Minute Walk Test
Time Frame
3 months
Title
FSHD Severity Score
Time Frame
3 months
Title
Quantitative muscle strength testing
Time Frame
3 months
Title
GPX3 Level
Description
Possible biomarker of disease severity in FSHD
Time Frame
3 months
Title
Step Counter
Description
Physical activity measure
Time Frame
3 months
Title
Laboratory safety monitoring
Description
bloods and urine safety testing (urea and electrolytes, urine plasma creatine:creatinine ratios)
Time Frame
3 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
5 Years
Maximum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Is between the ages of 5 and 18 years inclusive at the time of randomisation; Has a confirmed genetic diagnosis of Facioscapulohumeral Muscular Dystrophy (FSHD) types 1 or 2; Has a legally acceptable representative capable of understanding the informed consent document and providing consent on the participant's behalf. Exclusion Criteria: Has clinically significant elevation in plasma creatinine level or unexplained hypertension at screening; Has a prior diagnosis of chronic renal failure; Has a known hypersensitivity to creatine monohydrate of maltodextrin placebo; Patients already taking any medications to increase muscle bulk or strength or concomitant use of regular sodium valproate, corticosteroids of alpha agonists such as salbutamol.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Ian R Woodcock, MBBS
Organizational Affiliation
Murdoch Children Research Institute/Royal Children Hospital, Melbourne
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Monique M Ryan
Organizational Affiliation
Murdoch Children Research Institute/Royal Children Hospital, Melbourne
Official's Role
Principal Investigator
Facility Information:
Facility Name
The Royal Children's Hospital
City
Melbourne
State/Province
Victoria
ZIP/Postal Code
3052
Country
Australia

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Effect of Creatine Monohydrate on Functional Muscle Strength in Children With FSHD

We'll reach out to this number within 24 hrs